These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3219274)

  • 41. Conservative surgery and irradiation (QUART) in the treatment of 243 stage I-II breast cancer patients.
    Gasparini G; Panizzoni GA; Dal Fior S; Germani B; Dall'Antonia F; Segato G; Meli S; Pozza F
    Anticancer Res; 1991; 11(4):1635-40. PubMed ID: 1746920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.
    Hughes KS; Schnaper LA; Berry D; Cirrincione C; McCormick B; Shank B; Wheeler J; Champion LA; Smith TJ; Smith BL; Shapiro C; Muss HB; Winer E; Hudis C; Wood W; Sugarbaker D; Henderson IC; Norton L; ; ;
    N Engl J Med; 2004 Sep; 351(10):971-7. PubMed ID: 15342805
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
    Bertelsen L; Bernstein L; Olsen JH; Mellemkjaer L; Haile RW; Lynch CF; Malone KE; Anton-Culver H; Christensen J; Langholz B; Thomas DC; Begg CB; Capanu M; Ejlertsen B; Stovall M; Boice JD; Shore RE; ; Bernstein JL
    J Natl Cancer Inst; 2008 Jan; 100(1):32-40. PubMed ID: 18159070
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review.
    Hind D; Wyld L; Reed MW
    Br J Cancer; 2007 Apr; 96(7):1025-9. PubMed ID: 17285133
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
    Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG
    Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Christie hospital adjuvant tamoxifen trial--status at 10 years.
    Ribeiro G; Swindell R
    Br J Cancer; 1988 Jun; 57(6):601-3. PubMed ID: 3044432
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Corticosteroids for elderly patients with breast cancer.
    Minton MJ; Knight RK; Rubens RD; Hayward JL
    Cancer; 1981 Aug; 48(4):883-7. PubMed ID: 7272933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Hormone therapy in breast cancer: the end of tamoxifen?].
    Delozier T
    Bull Cancer; 2005 Feb; 92(2):142-50. PubMed ID: 15749643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tamoxifen in the management of advanced breast carcinoma in Nigerian women.
    Senbanjo RO; Ihekwaba FN; Ajayi OO
    West Afr J Med; 1990; 9(1):44-9. PubMed ID: 1702986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).
    Hind D; Wyld L; Beverley CB; Reed MW
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004272. PubMed ID: 16437480
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer.
    Buzzi F; Brugia M; Rossi G; Giustini L; Scoponi C; Sica G
    Anticancer Res; 1992; 12(3):869-71. PubMed ID: 1622145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
    Harris AL; Carmichael J; Cantwell BM; Dowsett M
    Br J Cancer; 1989 Jan; 59(1):97-9. PubMed ID: 2527049
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
    Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Megestrol acetate in the treatment of advanced post-menopausal breast cancer.
    Benghiat A; Cassidy SA; Davidson HE; Mancero FS; Pickard JG; Tyrrell CJ
    Eur J Surg Oncol; 1986 Mar; 12(1):43-5. PubMed ID: 3956753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.
    Lancet; 1987 Jul; 2(8552):171-5. PubMed ID: 2885637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.